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Abstract
Cannabinoid receptor‐1 (CB1) represents a potential drug target against conditions
that include obesity and substance abuse. However, drug trials targeting CB1 (encoded
by the CNR1 gene) have been compromised by differences in patient response. Toward
addressing the hypothesis that genetic changes within the regulatory regions
controlling CNR1 expression contribute to these differences, we characterized the
effects of disease‐associated allelic variation within a conserved regulatory sequence
(ECR1) in CNR1 intron 2 that had previously been shown to modulate cannabinoid
response, alcohol intake, and anxiety‐like behavior. We used primary cell analysis of
reporters carrying different allelic variants of the human ECR1 and found that human‐
specific C‐allele variants of ECR1 (ECR1(C)) drove higher levels of CNR1prom activity
in primary hippocampal cells than did the ancestral T‐allele and demonstrated a
differential response to CB1 agonism. We further demonstrate a role for the AP‐1
transcription factor in driving higher ECR1(C) activity and evidence that the ancestral t‐
allele variant of ECR1 interacted with higher affinity with the insulator binding factor
CTCF. The cell‐specific approaches used in our study represent an important step in
gaining a mechanistic understanding of the roles of noncoding polymorphic variation in
disease and in the increasingly important field of cannabinoid pharmacogenetics.
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1 | INTRODUCTION
The cannabinoid‐1 receptor (CB1) is expressed in areas of the nervous
system that include the hypothalamus and the hippocampus where CB1
plays a critical role in appetite regulation (Pomorska, do‐Rego, do‐Rego,
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Zubrzycka, & Janecka, 2016) and neuroprotection against stress
(Akirav, 2011). For this reason, CB1 has been explored as a target for
drugs to treat diseases, including obesity and depression (Huang, Chen,
& Zhang, 2016; Pomorska et al., 2016). However, problems with
potential side effects to drugs developed to target CB1 have delayed
the development of cannabinoids as potential drug therapies. For
example, the synthetic CB1 antagonist rimonabant, marketed as an
appetite suppressor, was withdrawn because 26% of patients reported
depression, anxiety, and feeling of suicidality (Lazary, Juhasz, Hunyady,
& Bagdy, 2011). The role of genetics in modulating cannabinoid
response is further supported by the findings of a strong genetic
component to the psychotic, cognitive, and addictive side effects of CB1
agonists (Hryhorowicz, Walczak, Zakerska‐Banaszak, Słomski, &
Skrzypczak‐Zielińska, 2018; Mandelbaum & de la Monte, 2017). Given
the potential benefits of the pharmacological manipulation of CB1, it is
essential to gain a better understanding of cannabinoid pharmacoge-
netics to facilitate the development and application of safe and effective
cannabinoid‐based therapeutics.
Previous studies have shown that the coding regions of the CNR1
gene, which encodes CB1, lack common nonsynonymous polymorphisms
that might account for differences in cannabinoid response. Thus, efforts
to understand the regulation of the CNR1 gene, and how it might be
affected by polymorphic variation, are currently underway. For example,
intron 2 of the human CNR1 gene contains a 3‐kb linkage disequilibrium
block (LD block) that contains 17 polymorphisms, two of which
rs2023239 and rs9450898, are associated with addictive behaviors
(Ketcherside, Noble, McIntyre, & Filbey, 2017), depression (Icick et al.,
2015), psychosis (Suárez‐Pinilla et al., 2015), reduced hippocampal
volume in cannabis abuse (Schacht, Hutchison, & Filbey, 2012), nicotine
addiction (Chen et al., 2008), obesity (Benzinou et al., 2008), and alcohol
abuse (Hutchison et al., 2008; Pava et al., 2012). Intriguingly, specific
haplotypes of the human CNR1 locus, which includes the rs2023239
locus, are associated with a significant reduction in CNR1 expression in
human hippocampus (Zhang et al., 2004) and a more recent paper
demonstrated that the G‐allele of rs2023239 was associated with a
greater expression of CNR1 messenger RNA (mRNA) in peripheral
lymphocytes (Ketcherside et al., 2017).
Subsequent studies of the CNR1 intron 2 LD block identified a
highly conserved and active enhancer (ECR1), which contained
a polymorphism (rs9444584; NC_000006.12:g.88152840C>T,
NC_000006.11:g.88862559C>T) in high LD with both rs2023239
(NC_000006.12:g.88150763T>C, NC_000006.11:g.88860482T>C)
and rs9450898 (NC_000006.12:g.88154344C>T, NC_000006.11:
g.88864063C>T; Figure 1b; Nicoll et al., 2012). Deletion of this
enhancer using CRISPR/CAS9 genome editing produced mice that
expressed less hippocampal CNR1mRNA, that drank less alcohol, had
altered levels of anxiety‐like behavior and had a blunted response
to cannabinoid‐1 receptor agonism (Hay, Cowie et al., 2019; Hay,
McEwan et al., 2019).
The current study examines the hypothesis that polymorphic
changes in the human ECR1 enhancer affect the activity of
CNR1prom in a tissue‐specific manner and also produce differential
activation of CNR1prom when challenged with a CB1 agonist. We
also explore the identity of the transcription factors that may
interact with the polymorphic regions of ECR1 and carry out
coexpression studies to determine the effects of their interactions
on regulatory activity. We discuss the possibility that the findings
described in this study represent an important step in our journey to
understand the role of regulatory variation in cannabinoid pharma-
cogenetics.
2 | MATERIALS AND METHODS
2.1 | Bioinformatic analysis using RegSNP
Prediction of the effects of allelic variants of rs9444584 on the
binding of transcription factors was predicted using the RegSNP
website (http://viis.abdn.ac.uk/regsnp/Home.aspx).
2.2 | Plasmid constructs
pCNR1prom‐Luc: The human genomic fragment containing the CNR1
promoter (CNR1prom) was amplified from human placental DNA
using the following primers (Zhang et al., 2004):
F IGURE 1 (a) Allelic variants of the ECR1 enhancer drive
differential activity of the cannabinoid receptor promoter in
different tissues. Diagrammatic representation of the reporter
constructs used in the current study demonstrating the relative
positions of the ECR1 element (light gray), the CNR1prom promoter
sequence (black) and reporter genes (white, firefly luciferase, not to
scale). (b) Dual luciferase analysis comparing the relative activity of
allelic variant of the ECR1 sequence in primary hypothalamic and
hippocampal cells magnetofected with pCNR1prom‐Luc
(CNR1prom), pECR1(C)‐luc (ECR1(C)) or pECR1(T)‐luc (ECR1(T))
(n = 14, error bars = standard deviation of the mean [SDM], **p < .01;
***p < .005, ns, no significance)
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CNR1prom forward 5′‐GATAACCTTTTCTAACCACCCACCTAG‐3′,
CNR1prom reverse 5′‐GCGGAAAAGAAGTGGAGAAG‐3′
and cloned into the EcoRI and SacI restriction sites of the pGL4.23
luciferase reporter construct to create the pCNR1prom‐Luc.
Production of pECR1(C)CNR1promLuc and pECR1(T)CNR1promLuc
firefly luciferase reporter constructs was achieved by cloning
the ECR1(C) or ECR1(T) regions from the pGEM‐Teasy parent constructs
using AatII and SalI sites and ligating into AatII and XhoI sites of the
pCNR1prom‐Luc placing ECR1(C) or ECR1(T) upstream of the CNR1prom
fragment to form pECR1(C)Luc and pECR1(T)Luc (Figure 1a).
2.3 | Primary cell culture
One‐day‐old male and female Sprague‐Dawley neonate rats were
euthanized in accordance with current UK Home Office schedule 1
guidelines. Hippocampal or hypothalamic tissues were dissected
into ice cold Neurobasal‐A medium (Life Technologies). Cells were
dissociated using a combination of trypsin and papain solution
followed by gentle agitation from pooled tissues to reduce
variability and cultured in poly‐D‐lysine coated 24‐well plates as
previously described (Nicoll et al., 2012) at a density of 180,000
cells per well as assessed using a Biorad TC10 cell viability counter
(Biorad). Cells were maintained at 37°C in 5% CO2 for up to 7 days
in vitro in Neurobasal‐A medium supplemented with 2% B27,
2 mM L‐glutamine, 50 μg/ml Streptomycin, and 50 U Penicillin
(Life Technologies) with the medium changed on the first day after
plating and then every 3 days. Cultures were transfected 4 days
after plating with luciferase plasmids (Figure 2a) plus renilla
luciferase plasmid (pGL4.74) as a transfection normalization
control. Neuromag transfection reagent was used as per the
manufacturer's instructions (OZ Biosciences). Finally, 24 hr after
transfection cultures were treated with the CB1 agonist
Win55,212‐2 (Pertwee et al., 2010) for a further 24 hr.
2.4 | Transformed cell culture and transfection
To determine whether c‐fos interacted with the ECR1 enhancer, we
cotransfected different genotypes of the ECR1 enhancer driving
the CNR1prom within a luciferase reporter in the presence/absence
of an empty expression vector (pcDNA3) or an expression vector
expressing the c‐fos protein into the SH‐SY5Y neuroblastoma cell
line. SH‐SY5Y cells (94030304; ECAC, UK) were cultured in
Dulbecco's modified Eagle medium (Gibco, UK) containing low
glucose (5.5 mM), L‐glutamine (4 mM), and sodium pyruvate (1mM).
Medium was supplemented with 10% (v/v) heat‐inactivated fetal
bovine serum (Gibco) and 1% (v/v) Penicillin–Streptomycin
(Pen‐Strep; Gibco). The cells were cotransfected with luciferase
reporter plasmids (Figure 2a) or a positive control (pAP1‐3; Addgene;
71258) and a renilla normalization control (pGL4.74; Promega, UK)
together with pcDNA‐FLAG‐FosWT (Addgene; 8966) or empty
expression vector (pcDNA3.1; Thermo Fisher Scientific; V79020)
plasmid using jetPRIME as per the manufacturer's instruction
(Polyplus Illkirch, France).
2.5 | Luciferase reporter assays
All luciferase reporter assays were performed either 24 (SH‐SY5Y
cells) or 48 hr (primary cells) after transfection as per the
manufacturer's instructions (Promega). Luciferase expression was
quantified using Dual Luciferase Reporter assay system and a
GloMax 96 microplate luminometer (Promega).
Chromatin immunoprecipitation (ChIP) was performed on
chromatin derived from primary hippocampal neurons transfected
with either the ECR1(C) or ECR1(T) reporter constructs (1.2 µg/
5 × 106 cells in 10 cm plates), as described above, and incubated
for 48 hr. Briefly, following cross linking with formaldehyde
hippocampal chromatin was extracted and fragmented by restric-
tion digestion (NcoI/BglII and MluI/AseI) or sonication as pre-
viously described (Carey, Peterson, & Smale, 2009) and incubated
in the presence of a mouse immunoglobulin G antibody (Upstate),
anti‐CTCF (Abcam) or anti‐Jun antibody (Sigma). Chromatin–anti-
body complexes were recovered using preblocked (1 mg/ml bovine
serum albumin and 1 μg/ml salmon sperm DNA) Dynabeads
Protein A (Life Technologies).
Quantitative real‐time polymerase chain reaction (PCR) for ChIP
samples: quantitative PCR (qPCR) for ChIP samples was conducted
using SYBR green reagents as per manufacturer's instructions
(Roche) using the following primers to normalize transfection
efficiencies from input DNA (LucChIP forward; CTTGCAGTTCTT-
CATGCCCG, LucChIP reverse; CTCACGAATACGACGGTGGG) and
to assess immunoprecipitation of human ECR1T or ECR1C allelic
variants following immunoprecipitation (hECR1 forward; TTAATGG
CAGCTACATCCCC, hECR1 reverse; TCATGGCAGGAAAACTGCTC).
F IGURE 2 The C‐allele of the ECR1 allele permits autoregulation of
the CNR1 promoter while the T‐allele acts as a repressor. Dual luciferase
analysis of primary hippocampal cells magnetofected with pECR1(C)‐luc
(pECR1(C)) or pECR1(T)‐luc (pECR1(T)) constructs and treated with
vehicle (white bars) or Win55,212‐2 (100nM; black bars) for 24 hr (n=6,
error bars = SDM, *p< .05, **p< .01). Win55,212‐2 treated dual luciferase
results (black bars) were normalized against the DMSO‐treated results
(white bars) for clarity. SDM, standard deviation of the mean. SDM,
standard deviation of the mean
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2.6 | Data analysis
Two‐tailed unpaired parametric Student's t test was used to examine
the difference between two groups. Where there were more than
two groups, statistical significance of data sets was analyzed using a
one‐way analysis of variance with Bonferroni post hoc tests. All tests
were carried out using GraphPad PRISM version 5.02 (GraphPad
Software, La Jolla, CA).
3 | RESULTS
3.1 | Allelic variants of the human ECR1 enhancer
differentially regulate the activity of CNR1prom
We had previously shown that the ECR1 enhancer could stimulate
the activity of a generic TATA box promoter when transfected into
different primary cell types and that the T‐alelle drove stronger
activity of this generic promoter (Nicoll et al., 2012). Because there is
extensive evidence of enhancer‐promoter selectivity in the genome
(Furlong & Levine, 2018), the current study sought to compare the
interactions of these different human ECR1 variants with the
previously characterized CNR1 promoter (CNR1prom; Zhang et al.,
2004). We produced a luciferase reporter construct supported by the
human CNR1prom fragment (pCNR1prom‐Luc), as previously
described (Zhang et al., 2004). We then cloned allelic variants of
ECR1 (ECR1C and ECR1T) into the pCNR1‐Luc construct (Figure 1a)
and magnetofected these constructs into rat hippocampal and
hypothalamic primary cell cultures. We then carried out dual
luciferase analysis of these transfected cell cultures 48 hr later. In
contrast to our previous studies, where we had shown that the
ancestral T‐allele drove stronger activity of the generic TATA box
promoter (Nicoll et al., 2012) we observed that the T‐allele failed to
enhance activity of CNR1prom in hippocampal‐derived cells and
actually repressed the activity of CNR1prom in cells derived from
hypothalamus. Instead, we observed strong enhancement of
CNR1prom activity by the C‐allele in hippocampal cells (Figure 1b)
demonstrating evidence of enhancer‐promoter specificity (Spurrell,
Dickel, & Visel, 2016) in the interaction of CNR1prom and ECR1(C) in
these cells.
3.2 | Allelic variants of ECR1 differentially
modulate the autoregulatory effects of CB1 agonism
on the CNR1 promoter
In keeping with previous observations (Borner, Hollt, Sebald, &
Kraus, 2007; Mukhopadhyay et al., 2010), we had shown that the
activity of the endogenous CNR1 gene and the activity of the
CNR1prom could be upregulated through pharmacological activation
of the CB1 receptor in both hippocampal‐ and hypothalamus‐derived
cells suggesting the possibility of a mechanistic autoregulatory loop
in the modulation of CNR1 expression in response to its stimulation
(Hay, Cowie et al., 2019; Hay, McEwan et al., 2019). Then, we asked
whether the C‐ and T‐alleles of ECR1 affected the response of
CNR1prom to agonist treatment. Reporter constructs containing
allelic variants of the ECR1 enhancer and CNR1prom were
magnetofected into hippocampal primary cell cultures which were
then treated with the CB1 agonist Win55,212‐2 (100 nM) as used in
previous studies (Pertwee et al., 2010). Dual luciferase analysis of
these cells demonstrated that incubation of cells with Win55,212‐2
significantly increased luciferase expression in the presence of the
ECR1(C) allele (Figure 2). However, we observed a significant
reduction in the response of CNR1prom to Win55,212‐2 treatment
in the presence of ECR1(T) suggesting that ECR1T does not support
autoregulation of CNR1prom in hippocampal cells and may even
repress its activity (Figure 2).
3.3 | ECR1(C) interacts with higher affinity to the
AP‐1 transcription factor than ECR1(T)
We next asked whether we could identify the putative protein–DNA
interactions responsible for the ability of ECR1(C) to upregulate the
activity of the CNR1 promoter. Bioinformatic analysis (RegSNP) of
the human ECR1 locus predicted that the AP‐1 transcription factor
(a dimer of the c‐FOS and c‐JUN proteins) would bind to ECR1(C)
with high affinity but with reduced affinity to ECR1(T). The RegSNP
program also suggested that the ECR1(T) allele would bind the CTCF
transcription factor with higher affinity. This is intriguing as CTCF is a
known marker for the function of regulatory sequences known as
insulators that protect promoters against the effects of enhancer
sequences (Agrawal, Heimbruch, & Rao, 2018).
To explore these predictions, we devised a novel primary cell‐
based assay that involved the magnetofection of human allelic variants
of ECR1 within the ECR1(C)‐Luc or ECR1(T)‐Luc plasmids (Figure 3a)
into primary rat hippocampal cell cultures. After 48 hr, chromatin was
extracted and fragmented using restriction digestion or sonication
(Figure 3a). qPCR of extracted chromatin using primer pairs designed
to detect the luciferase gene DNA on input DNA indicated equal
transfection efficiencies. The amount of luciferase DNA in the input
DNA was used to normalize the qPCR signal after immunoprecipita-
tion with antisera against the c‐JUN or CTCF proteins to ensure
transfection equivalence. After recovery of specific antibody–pro-
tein–DNA complexes qPCR specific for human ECR1 was used to
determine comparative levels of human ECR1 DNA immunoprecipita-
tion. Despite using three different genome fragmentation techniques
we consistently observed a higher signal from primary cells
transfected with ECR1CLuc compared with those transfected with
ECR1TLuc suggesting a significantly increased affinity for c‐JUN to the
C‐allele (Figure 3a,b). Intriguingly, we also observed increased binding
of CTCF to the T‐allele of ECR1 and were able to reproduce these
observations in two separate experiments (Figure 3c).
3.4 | c‐FOS overexpression increases the ability
of ECR1(C) but not ECR1(T) to activate CNR1prom
In addition to being a component of the AP‐1 transcription factor
c‐FOS is coexpressed with CNR1 in the hippocampus (Figure 4a) and
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it is known that upregulation of CB1 activity also increases activation
of c‐FOS (Marie‐Claire et al., 2003; Porcella, Gessa, & Pani, 1998). To
explore the possible functional relationship of c‐FOS with different
allelic variants of ECR1 we carried out a cotransfection analysis in a
human neuroblastoma cell line (SH‐SY5Y cells) with luciferase
reporters containing the C‐allele and T‐allele of ECR1 in combination
with an expression vector expressing the c‐FOS protein (pcDNA‐
FosWT). We observed that coexpression of c‐FOS with a luciferase
reporter containing a promoter known to respond strongly to AP‐1
(pAP1‐3) was highly upregulated (Figure 4b). We also observed a
significant increase in luciferase expression in cells cotransfected
with ECR1CLuc and pcDNA‐c‐FOS indicating that expression of
c‐FOS drives ECR1(C) to activate CNR1prom. However, consistent
with our previous primary cell transfection and ChIP data we
found no significant upregulation in activity of ECR1(T) in the
presence of c‐FOS expression (Figure 4b).
4 | DISCUSSION
Although targeting the CB1 receptor has clear therapeutic potential
the beneficial effects of cannabinoid drug treatments are not
F IGURE 3 The C‐allele of ECR1 binds the c‐jun protein with higher affinity than the T‐allele. (a) Bar graph demonstrating the results of four
separate ChIP assays performed on cross linked chromatin from primary hippocampal cells magnetofected with vectors containing either the
ECR(C) and ECR1(T) allelic variants. Before immunoprecipitation with c‐JUN chromatin was fragmented by endonuclease digestion (NcoI/BglII
or MluI/AseI) or sonication. All values have been normalized against the immunoglobulin G (IgG) immunoprecipitation signal and displayed as a
percentage of the input signal. (b) Statistical analysis (two‐tailed unpaired t test) of all of the ChIP assays displayed in (a) demonstrating the
relative levels of quantitative polymerase chain reaction signals received from DNA immunoprecipitated using the anti‐c‐JUN antibody. (c) Bar
graph demonstrating the results of two separate ChIP assays carried out as described above but using an anti‐CTCF antibody. Values have been
normalized against IgG controls and displayed as a proportion of input DNA (error bars = SDM; *p < .05). SDM, standard deviation of the mean
F IGURE 4 The C‐allele of ECR1 interacts more strongly with the c‐fos protein than does the T‐allele. In situ hybridization (Allen brain
atlas) of a coronal section of mouse midbrain comparing localization of (a) c‐FOS and (b) CNR1 messenger RNA (mRNA) within different regions
of the hippocampus (CA1, CA2, CA3, and dentate gyrus [DG]). (c) Results of a cotransfection study in SH‐SY5Y cells where different reporter
constructs (pCNR1prom‐Luc (CNR1prom), pECR1(C)‐luc (ECR1(C)) or pECR1(T)‐luc (ECR1(T)), pAP1‐3 (AP1‐3)), cotransfected with either
the empty expression vector (pcDNA3.1) or an expression vector expressing the c‐FOS protein. AP1‐3; pAP1‐3‐positive control plasmids
responsive to AP‐1 expression. All transfections were normalized against renilla luciferase (pGL4.74) and possible trans effects were negated
by normalizing against cells transfected with empty vector (n = 3, error bars = SDM, ns, not significant, *p < .05). SDM, standard deviation
of the mean
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universal (Hryhorowicz, Walczak, Zakerska‐Banaszak, Słomski, &
Skrzypczak‐Zielińska, 2017). Thus, understanding the pharmacoge-
netics of the CNR1 locus within the human population is essential to
the therapeutic development of the cannabinoids and being able to
select which members of the population would benefit most. Because
there is evidence that the majority of functional genomic variations
occurs outside of coding regions (Boyle, Li, & Pritchard, 2017) and
the CNR1 coding region does not contain polymorphisms that
occur in >1% of the population, the current study sought to better
understand the noncoding genetic influences controlling the tissue‐
specific expression of the CNR1 gene as possible contributory factors
in the pharmacogenomics of cannabinoid response.
Using a combination of linkage disequilibrium of disease‐associated
SNPs and comparative genomics we identified a polymorphic enhancer
sequence that we called ECR1 within intron 2 of the CNR1 locus
(Nicoll et al., 2012). Subsequent analysis showed that this sequence had
differential enhancer activity when cloned into a reporter construct
with a short generic TATA box promoter (Nicoll et al., 2012). Disrupting
the ECR1 enhancer element using CRISPR genome editing in mice
demonstrated that ECR1 is important for maintaining normal levels of
CNR1 expression within the hippocampus (Hay, Cowie et al., 2019; Hay,
McEwan et al., 2019). This experiment also permitted in vivo behavioral
studies to demonstrate the effects of ECR1 disruption on core body
temperature, following CB1 activation, and ethanol intake (Hay,
Cowie et al., 2019; Hay, McEwan et al., 2019). This last observation is
interesting as human ECR1 contains the rs9444584 polymorphism; part
of a haplotype block that has been implicated in reduced CNR1
expression (Zhang et al., 2004) and increasing susceptibility to alcohol
abuse (Hutchison et al., 2008; Pava et al., 2012). Thus, in addition to its
possible role in stratification of drug response, further functional
analysis of this polymorphism in vivo and in the clinic may reveal
important insights into the causes of alcohol abuse.
Intriguingly, our analysis of the interaction of different alleles of ECR1
with the endogenous CNR1 promoter contrasted strongly with that
previously published whereby the T‐allele of ECR1 drove stronger
activity of a generic TATA box promoter (Nicoll et al., 2012). Thus, in the
presence of the C‐allele of ECR1, the endogenous CNR1 promoter was
much more active that in the presence of the T‐allele in direct contrast to
their interaction with the small generic TATA box promoter previously
used. Indeed, to the best of our knowledge, this is the first time that such
a significant difference has been observed in the effects of two different
allelic variants of an enhancer on the activity of two different promoters.
Moreover, the interaction of the C‐allele with the endogenous promoter
is consistent with the observation that, in human hippocampus, the
haplotype associated with strongest expression of CNR1 was that
containing the C‐haplotype (Zhang et al., 2004). Although the specific
mechanisms involved can only be speculated on, we believe that the data
derived from our analysis of the interaction of the two allelic variants of
ECR1 with the CNR1 promoter is more representative of the endogenous
system so represents a more credible paradigm. This comparison also
suggests that caution should be exercised by those attempting to reach
conclusions pertaining to the effects of polymorphic variation in
enhancers based on their interaction with foreign promoters.
From the perspective of tissue‐specific regulation our observa-
tions suggest that ECR1 may play a more substantive role in
supporting expression of CNR1 in the hippocampus than the
hypothalamus implying that SNPs within ECR1 would have a greater
effect in the hippocampus. This observation is consistent with
previous observations in humans where a specific haplotype
involving SNPs in high LD with rs9444584 significantly reduced the
expression of CNR1 in the hippocampus (Zhang et al., 2004).
Considering the known neuroprotective role of CB1 activation
against the effects of stress in the hippocampus (Scarante et al.,
2017) it is possible that the C‐allele may play a role in protecting
the hippocampus against the depressive and anxiety inducing effects
of stress in humans. In this context, and from the perspective of
adaptive evolution, it is interesting that the C‐allele has undergone
positive selection in European and Asian populations where its
frequency exceeds 80% compared with the ancestral T‐allele.
Although bottleneck effects might account for this difference, we
cannot rule out the possibility that selection for an allele which drives
higher levels of CB1 receptor in the hippocampus may have been
beneficial to early human populations moving into challenging new
habitats by resisting the anxiety and depressive effects of stress.
These observed differences in the activity of the C‐ and T‐alleles of
ECR1 in the hippocampus may also influence the observed effects of
CB1‐targeted therapeutics such as the antiobesity drug rimonabant in
humans. Rimonabant's main mode of action is through antagonism/
inverse agonism of the CB1 receptor in the hypothalamus, which leads
to a reduction in appetite. Rimonabant was withdrawn from the
market as it was linked to an increase in depressed and suicidal
feelings in 26% of patients (Lazary et al., 2011). If we consider what is
known about the neuroprotective role of CB1 against stress in the
hippocampus, the increase in anxiety and depression in these
individuals is not surprising as the appetite reducing antagonism of
CB1 in the hypothalamus would be accompanied by antagonism of
CB1 in the hippocampus. Indeed, reports of increased anxiety
(O’Brien et al., 2013) and depression‐like (Beyer et al., 2010) behaviors
have been reported in rodents, who harbor the ancestral T‐allele of
ECR1, following chronic administration of rimonabant. What is
probably more noteworthy is the observation that 74% of patients
did not experience anxiety/depression‐like symptoms and responded
positively to rimonabant. Based on our observations, we propose that
the human‐specific C‐allele of ECR1 may induce higher levels of CB1
expression in the hippocampus in humans, thus protecting individuals
from the anxiolytic and depression forming effects of stress following
treatment with rimonabant (Akirav, 2011).
Our analysis goes on to identify a possible molecular mechanism
that may explain differences in the activity of the C‐ and T‐alleles of
ECR1 based on variable affinity to the c‐JUN and c‐FOS components
of the AP‐1 transcription factor which is known to be expressed in
the hippocampus. Using a unique experiment based on ChIP analyses
of magnetofected primary hippocampal cells we demonstrated
increased affinity for c‐JUN to the C‐allele of ECR1(C). To verify
this observation, we also showed that expression of c‐FOS; one of
the proteins that forms the AP‐1 complex, activates the ECR1(C)
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enhancer but not ECR1(T) in cotransfected cells. This observation
was interesting as several studies have demonstrate that stimulation
of CB1 induces binding of AP‐1 to DNA and expression of c‐FOS
(Marie‐Claire et al., 2003; Porcella et al., 1998). This was particularly
evident in the hippocampus where CB1 and c‐FOS are coexpressed in
the CA1, CA3, and dentate gyrus (Derkinderen et al., 2003).
Our observations also touch on the evolution of the C‐allele which is
only found in humans. We were able to predict binding of the CTCF
transcription factor; a known marker of insulator function, with higher
affinity to the T‐allele, a prediction that we also support using ChIP
assays. These observations raise an interesting possibility that the
ancestral T‐allele of ECR1 could act as a weak enhancer with insulator
properties in the hippocampus of most vertebrates. However, the
change to the C‐allele in humans, that increased binding affinity of AP‐1
and increased the enhancer like properties of ECR1 in specific tissues,
may have proved advantageous to specific populations faced with new
and stressful circumstances thus expanding the frequency of the
C‐allele in these populations.
Taken together, the evidence discussed above suggests a role for
allelic variation within ECR1 in modulating the activity of CNR1prom
and thus expression of CNR1 and a mechanism is proposed based on
the evidence. Although much remains to be done to conclusively
establish a role for these observations in alcohol abuse and drug effects
in humans, our unique primary cell‐based ChIP transfection studies and
reporter‐expression vector coexpression studies lay the foundation for
future studies of the contribution of these genetic and epigenetic
factors in the pharmacogenetics of the cannabinoids and the possible
effects on human health and disease susceptibility. We believe that the
current manuscript provides not only a platform for the further study
of the effects of polymorphisms on the pharmacogenomics of the
cannabinoids but also an important functional tool for understanding
the role of noncoding polymorphisms in health and disease.
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